Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Total Liabilities (2020 - 2025)

Biofrontera has reported Total Liabilities over the past 6 years, most recently at $18.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 2.35% year-over-year to $18.1 million; the TTM value through Dec 2025 reached $18.1 million, up 2.35%, while the annual FY2025 figure was $18.1 million, 2.35% up from the prior year.
  • Total Liabilities for Q4 2025 was $18.1 million at Biofrontera, roughly flat from $18.0 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $41.9 million in Q4 2021 and troughed at -$7.2 million in Q2 2023.
  • A 5-year average of $21.0 million and a median of $24.0 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: skyrocketed 2560.31% in 2022 and later tumbled 119.71% in 2023.
  • Year by year, Total Liabilities stood at $41.9 million in 2021, then tumbled by 35.52% to $27.0 million in 2022, then dropped by 14.32% to $23.1 million in 2023, then decreased by 23.64% to $17.7 million in 2024, then increased by 2.35% to $18.1 million in 2025.
  • Business Quant data shows Total Liabilities for BFRI at $18.1 million in Q4 2025, $18.0 million in Q3 2025, and $24.8 million in Q2 2025.